{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T23:26:46Z","timestamp":1762298806042,"version":"3.37.3"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,6,13]],"date-time":"2018-06-13T00:00:00Z","timestamp":1528848000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s10072-018-3471-6","type":"journal-article","created":{"date-parts":[[2018,6,13]],"date-time":"2018-06-13T10:15:47Z","timestamp":1528884947000},"page":"1773-1774","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Ipilimumab treatment associated with myasthenic crises and unfavorable disease course"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2122-1016","authenticated-orcid":false,"given":"Eda","family":"Derle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibel","family":"Benli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,13]]},"reference":[{"key":"3471_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0455-8","volume":"13","author":"A Bertrand","year":"2015","unstructured":"Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T (2015) Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med 13:211. \n                    https:\/\/doi.org\/10.1186\/s12916-015-0455-8","journal-title":"BMC Med"},{"issue":"2","key":"3471_CR2","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","volume":"2","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, Guminski A, Puzanov I, Lawrence DP, Buchbinder EI, Mudigonda T, Spencer K, Bender C, Lee J, Kaufman HL, Menzies AM, Hassel JC, Mehnert JM, Sosman JA, Long GV, Clark JI (2016) Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2(2):234\u2013240. \n                    https:\/\/doi.org\/10.1001\/jamaoncol.2015.4368","journal-title":"JAMA Oncol"},{"issue":"1","key":"3471_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/mus.26070","volume":"58","author":"Noah A. Kolb","year":"2018","unstructured":"Kolb NA, Trevino CR, Waheed W, Sobhani F, Landry KK, Thomas AA, Hehir M (2018) Neuromuscular complications of immune checkpoint inhibitor therapy. Muscle Nerve. \n                    https:\/\/doi.org\/10.1002\/mus.26070","journal-title":"Muscle & Nerve"},{"key":"3471_CR4","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","volume":"82","author":"D Makarious","year":"2017","unstructured":"Makarious D, Horwood K, Coward JIG (2017) Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer 82:128\u2013136. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2017.05.041","journal-title":"Eur J Cancer"},{"issue":"11","key":"3471_CR5","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1080\/14740338.2017.1372421","volume":"16","author":"M Perez-De-Lis","year":"2017","unstructured":"Perez-De-Lis M, Retamozo S, Flores-Chavez A, Kostov B, Perez-Alvarez R, Brito-Zeron P, Ramos-Casals M (2017) Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS registry). Expert Opin Drug Saf 16(11):1255\u20131271. \n                    https:\/\/doi.org\/10.1080\/14740338.2017.1372421","journal-title":"Expert Opin Drug Saf"},{"issue":"10","key":"3471_CR6","doi-asserted-by":"publisher","first-page":"6430","DOI":"10.4049\/jimmunol.166.10.6430","volume":"166","author":"HB Wang","year":"2001","unstructured":"Wang HB, Shi FD, Li H, Chambers BJ, Link H, Ljunggren HG (2001) Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis. J Immunol 166(10):6430\u20136436","journal-title":"J Immunol"},{"issue":"3","key":"3471_CR7","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/mus.25055","volume":"54","author":"J Zhu","year":"2016","unstructured":"Zhu J, Li Y (2016) Myasthenia gravis exacerbation associated with pembrolizumab. Muscle Nerve 54(3):506\u2013507. \n                    https:\/\/doi.org\/10.1002\/mus.25055","journal-title":"Muscle Nerve"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10072-018-3471-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-018-3471-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-018-3471-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T19:17:56Z","timestamp":1560367076000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10072-018-3471-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,13]]},"references-count":7,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["3471"],"URL":"https:\/\/doi.org\/10.1007\/s10072-018-3471-6","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"type":"print","value":"1590-1874"},{"type":"electronic","value":"1590-3478"}],"subject":[],"published":{"date-parts":[[2018,6,13]]},"assertion":[{"value":"17 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}